Want to see BCAB full AI Analyst Report?
BCAB Stock Chart & Stats
$3.37
$0.00(0.00%)
At close: 4:00 PM EDT
$3.37
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.81 - $71.50
Previous CloseN/A
Volume9.08K
Average Volume (3M)56.22K
Market Cap
$5.30M
Enterprise Value$11.20
Total Cash (Recent Filing)$1.54M
Total Debt (Recent Filing)$5.86M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.45
Shares Outstanding1,666,100
10 Day Avg. Volume38,648
30 Day Avg. Volume56,215
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.92
Price to Sales (P/S)16.70
P/FCF Ratio-0.69
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CAB Oncology PlatformThe CAB platform provides a differentiated approach to developing antibody-based cancer therapies by targeting activation within tumors. If clinical validation continues, this design could support better tolerability and efficacy across multiple solid-tumor programs.
Revenue ReboundThe sharp TTM revenue increase indicates improved collaboration, licensing, or research-related income generation. Although revenue remains volatile and non-recurring product sales are absent, higher inflows could help fund development and reduce reliance on financing.
Governance StabilityShareholder support for directors, the auditor, and executive compensation reduces near-term governance uncertainty. Stable oversight can help management execute the clinical strategy and maintain partner and investor confidence during ongoing development.
Bears Say
Negative Stockholders' EquityNegative equity signals a materially weakened capital base and limits financial flexibility. Shrinking assets alongside continued losses may constrain investment in clinical programs and increase dependence on equity issuance or other external funding.
Persistent Cash BurnOngoing negative operating cash flow means the company cannot currently fund operations internally. Even though burn improved from approximately $48.2M in 2025, continued clinical spending creates recurring financing needs and potential dilution risk.
Deep Clinical-Stage LossesThe company remains far from breakeven, with no established commercial product revenue and deeply negative profitability. Its clinical-stage model requires substantial investment before potential approvals, leaving results dependent on development progress and funding access.
BioAtla News
BCAB FAQ
What was Bioatla, Inc.’s price range in the past 12 months?
Bioatla, Inc. lowest stock price was $2.81 and its highest was $71.50 in the past 12 months.
What is Bioatla, Inc.’s market cap?
Bioatla, Inc.’s market cap is $5.30M.
When is Bioatla, Inc.’s upcoming earnings report date?
Bioatla, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 84 days.
How were Bioatla, Inc.’s earnings last quarter?
Bioatla, Inc. released its earnings results on Aug 06, 2026. The company reported $0.272 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Bioatla, Inc. overvalued?
According to Wall Street analysts Bioatla, Inc.’s price is currently Overvalued.
Does Bioatla, Inc. pay dividends?
Bioatla, Inc. does not currently pay dividends.
What is Bioatla, Inc.’s EPS estimate?
Bioatla, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioatla, Inc. have?
Bioatla, Inc. has 1,666,100 shares outstanding.
What happened to Bioatla, Inc.’s price movement after its last earnings report?
Bioatla, Inc. reported an EPS of $0.272 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.15%.
Which hedge fund is a major shareholder of Bioatla, Inc.?
Currently, no hedge funds are holding shares in BCAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioatla, Inc.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Technical Analysis
Actinium Pharmaceuticals
―
―
Lantern Pharma
―
Century Therapeutics
―
MAIA Biotechnology, Inc.
―
Ownership Overview
27.02% Insiders
11.77% Mutual Funds
1.02% Other Institutional Investors
59.19% Public Companies and
Individual Investors